Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Long-term Effects of Salmeterol/Fluticasone Propionate (Seretide tm) 50/500mcg BD, Salmeterol 50mcg BD and Fluticasone Propionate 500mcg BD, All Delivered Via the Diskus tm/Accuhaler tm Inhaler, on Mortality and Morbidity of Subjects With Chronic Obstructive Pulmonary Disease (COPD) Over 3 Years of Treatment
Brief Summary: The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.


Options:
A: Intervention Type: DRUG; Name: budesonide/formoterol, 2x 200/6 microgram. 4 times daily; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: prednisolone, 30 mg once daily and placebo; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
C: Arm Label: Symbicort then Formoterol then Placebo; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol Turbuhaler 320/9µg, Drug: formoterol Turbuhaler 9µg, Other: Placebo | Arm Label: Formoterol then Symbicort then Placebo; Type: EXPERIMENTAL; Interventions: Drug: budesonide/formoterol Turbuhaler 320/9µg, Drug: formoterol Turbuhaler 9µg, Other: Placebo | Arm Label: Placebo then Formoterol then Symbicort; Type: PLACEBO_COMPARATOR; Interventions: Drug: budesonide/formoterol Turbuhaler 320/9µg, Drug: formoterol Turbuhaler 9µg, Other: Placebo | Intervention Type: DRUG; Name: budesonide/formoterol Turbuhaler 320/9µg; Assigned to Arm(s): Formoterol then Symbicort then Placebo, Placebo then Formoterol then Symbicort, Symbicort then Formoterol then Placebo | Intervention Type: DRUG; Name: formoterol Turbuhaler 9µg; Assigned to Arm(s): Formoterol then Symbicort then Placebo, Placebo then Formoterol then Symbicort, Symbicort then Formoterol then Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Formoterol then Symbicort then Placebo, Placebo then Formoterol then Symbicort, Symbicort then Formoterol then Placebo
D: Arm Label: MF/F MDI 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) combination | Arm Label: MF MDI 400 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate MDI (MF MDI) | Arm Label: Formoterol MDI 10 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Formoterol MDI | Arm Label: Placebo MDI BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 400/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) combination; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Mometasone furoate MDI (MF MDI); Assigned to Arm(s): MF MDI 400 mcg BID | Intervention Type: DRUG; Name: Formoterol MDI; Assigned to Arm(s): Formoterol MDI 10 mcg BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo MDI BID

Answer: B